Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

787 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biological characteristics of luminal subtypes in pre- and postmenopausal estrogen receptor-positive and HER2-negative breast cancers.
Murase K, Yanai A, Saito M, Imamura M, Miyagawa Y, Takatsuka Y, Inoue N, Ito T, Hirota S, Sasa M, Katagiri T, Fujimoto Y, Hatada T, Ichii S, Nishizaki T, Tomita N, Miyoshi Y. Murase K, et al. Among authors: miyagawa y. Breast Cancer. 2014 Jan;21(1):52-7. doi: 10.1007/s12282-012-0348-z. Epub 2012 Feb 23. Breast Cancer. 2014. PMID: 22359195
Association of body mass index with risk of luminal A but not luminal B estrogen receptor-positive and HER2-negative breast cancer for postmenopausal Japanese women.
Miyagawa Y, Miyake T, Yanai A, Murase K, Imamura M, Ichii S, Takatsuka Y, Ito T, Hirota S, Saito M, Kotoura Y, Miyauchi K, Fujimoto Y, Hatada T, Sasa M, Miyoshi Y. Miyagawa Y, et al. Breast Cancer. 2015 Jul;22(4):399-405. doi: 10.1007/s12282-013-0493-z. Epub 2013 Sep 3. Breast Cancer. 2015. PMID: 24000037
High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A, Yagi T, Yanai A, Miyagawa Y, Enomoto Y, Murase K, Imamura M, Takatsuka Y, Sakita I, Hatada T, Miyoshi Y. Nishimukai A, et al. Among authors: miyagawa y. Clin Breast Cancer. 2015 Jun;15(3):204-11. doi: 10.1016/j.clbc.2014.12.007. Epub 2014 Dec 24. Clin Breast Cancer. 2015. PMID: 25600243
High levels at baseline of serum pyridinoline crosslinked carboxyterminal telopeptide of type I collagen are associated with worse prognosis for breast cancer patients.
Imamura M, Nishimukai A, Higuchi T, Ozawa H, Yanai A, Miyagawa Y, Murase K, Sakita I, Hatada T, Takatsuka Y, Katagiri T, Miyoshi Y. Imamura M, et al. Among authors: miyagawa y. Breast Cancer Res Treat. 2015 Dec;154(3):521-31. doi: 10.1007/s10549-015-3638-2. Epub 2015 Nov 16. Breast Cancer Res Treat. 2015. PMID: 26573829
787 results